Business Context and Reporting Period
Company: Rexahn Pharmaceuticals, Inc. (Note: Metadata listed "Opus Genetics," but filing text confirms Rexahn Pharmaceuticals, a development-stage biopharmaceutical company).
Reporting Period: Quarterly period ended September 30, 2010 (Form 10-Q).
Business Overview: The Company is focused on the discovery and development of treatments for cancer, CNS disorders, and sexual dysfunction. It has no commercial product sales to date and relies on equity financing and collaboration agreements to fund operations. Key drug candidates include Archexin (cancer), Serdaxin (depression), and Zoraxel (erectile dysfunction).
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 2010 | 9 Months Ended Sep 30, 2009 | 3 Months Ended Sep 30, 2010 |
|---|---|---|---|
| Revenues | $56,250 | $56,250 | $18,750 |
| Net Loss | $(6,995,912) | $(4,505,045) | $(2,318,108) |
| Loss Per Share (Basic/Diluted) | $(0.09) | $(0.08) | $(0.03) |
| Cash Used in Operating Activities | $(4,566,843) | $(3,758,540) | N/A |
| Cash Provided by Financing Activities | $12,688,844 | $6,085,851 | N/A |
| Cash and Cash Equivalents (End of Period) | $15,829,783 | $4,141,358 | N/A |
| Total Assets | $18,290,302 | N/A | N/A |
| Accumulated Deficit | $(43,289,819) | N/A | N/A |
Debt and Liquidity: The Company has no long-term debt outstanding as of September 30, 2010. Total liabilities were $2,398,151, primarily consisting of accounts payable and deferred revenue. The Company holds $1,183,606 in restricted cash equivalents related to a letter of credit and a research agreement with Teva.
Material Changes vs. Prior Period
- Revenue: Remained flat at $56,250 for the nine-month period, derived entirely from the amortization of a deferred revenue agreement with Rexgene Biotech Co., Ltd.
- Expenses:
- General and Administrative (G&A): Increased 93.5% to $4,423,376 (9 months 2010) from $2,285,804 (9 months 2009). The primary driver was $1,663,999 in compensatory stock issued for investor relations services.
- Research and Development (R&D): Increased 24.3% to $2,509,600 (9 months 2010) from $2,018,766 (9 months 2009), driven by the completion of Phase IIA trials and commencement of Phase IIB trials for Archexin and Serdaxin, plus pre-clinical work on RX-3117.
- Net Loss: Widened significantly to $6,995,912 for the nine months ended September 30, 2010, compared to $4,505,045 in the prior year period.
- Cash Position: Cash and cash equivalents increased by $8,531,751 during the nine-month period, primarily due to $9.3 million in proceeds from a private placement of common stock and $3.3 million from warrant exercises.
Guidance, Outlook, and Risks
Outlook and Capital Needs: Management believes existing cash resources ($15.8 million) are sufficient to cover operating needs through December 31, 2011. The Company expects to spend approximately $8 million on clinical development for Archexin, Serdaxin, and Zoraxel over the next 12 months, plus $5 million on general corporate expenses. Additional financing will be required to fully fund the development plan.
Key Risks and Contingencies:
- Going Concern: The Company has an accumulated deficit of $43.3 million and has not generated commercial revenue. Continued losses are anticipated.
- Regulatory Approval: Success depends on obtaining FDA approval for drug candidates, which is uncertain and costly.
- Legal Proceedings: A lawsuit with Amarex, LLC was settled in June 2010. Amarex executed a promissory note to pay the Company $56,047 in installments.
- Contractual Obligations: The Company has committed to spending $2,000,000 (with $1.13 million remaining) on the pre-clinical development of RX-3117 under an agreement with Teva Pharmaceutical Industries Limited.
Investor Verification Checklist
- Cash Runway: Verify if the $15.8 million cash balance is sufficient to fund the projected $8 million clinical spend and $5 million corporate spend through 2011 without further dilution.
- Revenue Recognition: Confirm the sustainability of the $56,250 quarterly revenue, which is solely from the amortization of a 2003 agreement with Rexgene and not from product sales.
- Stock-Based Compensation: Review the impact of the $1.66 million in stock issued for investor relations services on future G&A expenses and shareholder dilution.
- Clinical Trial Progress: Monitor the status of Phase IIb trials for Serdaxin (depression) and Zoraxel (erectile dysfunction), and the Phase IIa trial for Archexin (pancreatic cancer), as delays could increase costs significantly.
- Restricted Cash: Note that $1.18 million of cash is restricted and unavailable for general operations, tied to the Teva agreement and a lease letter of credit.